Hubbry Logo
EugeroicEugeroicMain
Open search
Eugeroic
Community hub
Eugeroic
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Eugeroic
Eugeroic
Eugeroic
View on Wikipedia
from Wikipedia
Eugeroic
Drug class
The chemical structure of modafinil, the prototypical drug of this class
Class identifiers
SynonymsEugrégorique; Eugregorique; Eugregoric; Vigilance-promoting agent
UseTo increase wakefulness and arousal, to reduce sleepiness and sedation
ATC codeN06B
Legal status
In Wikidata

A eugeroic, or eugregoric, is a type of drug that increases wakefulness.[1][2][3][4] The term has been used inconsistently and in multiple ways in the scientific literature, either to refer specifically to modafinil-type wakefulness-promoting agents or to refer to wakefulness-promoting agents generally.[1][5][6][7] It was first introduced in the French literature in 1987 as a descriptor for modafinil-like wakefulness-promoting drugs and for purposes of distinguishing such drugs from psychostimulants.[1] However, the term "eugeroic" has not been widely adopted in the literature, and instead the term "wakefulness-promoting agent" (and variations thereof) has been more widely used, both for modafinil-type drugs and other agents.[1][8][9][10]

Eugeroics, in the sense of modafinil-type wakefulness promoting agents, include modafinil itself, armodafinil, and adrafinil, among others.[9] They are medically indicated for the treatment of certain sleep disorders, including excessive daytime sleepiness (EDS) in narcolepsy or obstructive sleep apnea (OSA).[3][4] Eugeroics are also often prescribed off-label for the treatment of EDS in idiopathic hypersomnia.[11] In contrast to classical psychostimulants, such as amphetamine and methylphenidate, which are also used in the treatment of these disorders, eugeroics typically do not produce euphoria, and, consequently, have lower misuse potential.[3][4][12]

Modafinil and armodafinil are thought to act as selective, weak, atypical dopamine reuptake inhibitors (DRIs).[13][3][4] However, additional actions are also possible and have not been ruled out.[13] Adrafinil acts as a prodrug of modafinil and hence shares its mechanism of action.[13] Certain other drugs acting as atypical DRIs with known or potential wakefulness-promoting effects include solriamfetol (also a norepinephrine reuptake inhibitor),[14][15] vanoxerine,[16] phenylpiracetam,[17][18][19] and mesocarb.[20][21][22][23] Other wakefulness-promoting agents act in a variety of other ways.[16][1][10][24]

List of eugeroics

[edit]

Marketed

[edit]

Discontinued

[edit]
  • Adrafinil (Olmifon, CRL-40028, N-hydroxymodafinil) – a hydroxy-substituted derivative and prodrug of modafinil

Never marketed

[edit]
  • Esmodafinil (CRL-40983, (S)-modafinil) – the (S)-enantiomer of modafinil
  • Fladrafinil (CRL-40941, fluorafinil, bisfluoroadrafinil) – a bisfluoro-substituted derivative of adrafinil
  • Flmodafinil (CRL-40940, NLS-4, JBG01-41, bisfluoromodafinil, lauflumide) – a bisfluoro-substituted derivative of modafinil
  • Fluorenol ("hydrafinil") – a novel eugeroic structurally unrelated to modafinil and its analogues
  • Modafiendz (methylbisfluoromodafinil) – a methyl and bisfluoro-substituted derivative of modafinil

Novel eugeroics

[edit]
See also: List of modafinil analogues and derivatives

The pharmaceutical company Cephalon, the original United States market rights holder of modafinil, has demonstrated initiative in the development of a successor to the prototypical eugeroic.[25] Of the more than twenty compounds preclinically tested in Cephalon's three-part drug discovery series, the compound fluorenol was selected as a lead.[26] Fluorenol was found to induce wakefulness to a greater degree than modafinil, despite possessing a lower affinity for the dopamine transporter (DAT).[26] Many other modafinil analogues have also subsequently been developed, not specifically as wakefulness-promoting agents but for treatment of conditions like psychostimulant use disorder and motivational disorders.[27][28][29][17]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Eugeroic

View on Grokipedia
from Grokipedia
Eugeroics are a class of atypical psychostimulants designed to promote and through "," distinguishing them from traditional stimulants by avoiding common side effects such as interference with recovery sleep, excessive locomotor activity, or anxiety induction. The term "eugeroic" originates from Greek words meaning "good" and "," reflecting their targeted enhancement of vigilance without the broad sympathomimetic effects of amphetamines or . The leading example is , approved by the U.S. (FDA) in December 1998 for treating associated with , , and . Related compounds include , a of , and , its longer-acting R-enantiomer approved by the FDA in 2007, both sharing similar wake-promoting profiles. Although their exact mechanisms are not fully elucidated, eugeroics primarily increase extracellular levels by weakly inhibiting the , while also activating (hypocretin) neurons in the and stimulating alpha-1 adrenergic receptors to sustain . Clinically, they are used to manage disorders of excessive and have shown efficacy in investigational and off-label applications for alleviating in conditions like cancer-related tiredness and post-stroke , with a of 12–15 hours enabling once-daily dosing. Unlike classical stimulants, eugeroics exhibit low abuse potential due to their selective effects and minimal peripheral sympathomimetic activity, though prolonged use may increase cardiovascular risks such as elevated and , and has been associated with modulation of immune responses.

Definition and Classification

Definition

Eugeroics constitute a class of psychoactive drugs designed to promote and , distinguished from classical stimulants like amphetamines by their lack of typical side effects, such as interference with recovery or excessive jitteriness. This category includes agents that enhance vigilance through mechanisms that avoid the broad sympathomimetic activation seen in traditional psychostimulants. The term "eugeroic" originates from the Greek roots "eu," meaning "good," and "egero," from "egerō," meaning "to arouse" or "wake up," collectively signifying "good arousal." Coined to describe this novel pharmacological profile, it emphasizes the drugs' ability to induce sustained mental without the disruptive effects of amphetamine-like compounds. In clinical practice, eugeroics primarily serve to alleviate linked to sleep disorders, such as , , and . For instance, , a prototypical eugeroic, is approved by the for improving in patients with these conditions, thereby supporting daily functioning without inducing or dependency common to other stimulants. Eugeroics differ fundamentally from sedatives and hypnotics, which suppress activity to induce relaxation or ; instead, eugeroics selectively bolster arousal pathways to maintain cognitive performance and reduce . This targeted enhancement of vigilance positions them as therapeutic options for disorders characterized by pathological sleepiness rather than .

Classification

Eugeroics are classified as a subclass of (CNS) stimulants, specifically atypical due to their selective promotion of with minimal impact on mood or motor activity, and notably lower potential for abuse and dependence compared to traditional stimulants. This distinction arises from their reduced euphoric effects and lower risk of addiction, as evidenced by clinical studies showing limited reinforcing properties in animal models and subjects. Within eugeroics, subclassification often follows , with the prototypical group comprising diphenylmethyl sulfinyl derivatives, such as (2-[(diphenylmethyl)sulfinyl]acetamide), , and , which share a core moiety linked to a diphenylmethyl group. In contrast, other wake-promoting agents included under the broader eugeroic umbrella, like and , belong to distinct structural classes; is a derivative acting as a dual dopamine-norepinephrine , while is a . Eugeroics differ from amphetamines and , which are classic CNS stimulants that induce , heightened sympathetic activity, and significant abuse liability through broad catecholamine release, whereas eugeroics primarily enhance sustained via more targeted inhibition without comparable psychoactive . They also contrast with agonists, such as investigational compounds like danavorexton, which promote by directly mimicking neuropeptides to stabilize circuits, rather than modulating monoamine transporters. This unique profile positions eugeroics as vigilance enhancers focused on cognitive over general stimulation. Under international drug control conventions, representative eugeroics like are typically scheduled as low-risk substances; in , it is classified as a Schedule IV by the , reflecting its modest potential for misuse relative to Schedule II stimulants like amphetamines. Similar classifications apply in many countries, emphasizing controlled prescription access without stringent restrictions.

History

Discovery and Early Development

Eugeroics trace their origins to the 1970s, when French pharmaceutical company Laboratoire L. Lafon initiated a research program aimed at developing treatments for and related sleep disorders. In 1974, chemists at Lafon discovered during screening of compounds for activity, identifying it as a promising agent to promote without the typical side effects of amphetamines. Adrafinil was initially tested in animal models, where it demonstrated vigilance-enhancing properties, leading to its further pursuit as a novel therapeutic for . Pharmacokinetic investigations of in 1976 revealed as its primary , prompting its isolation and separate evaluation. Early animal studies confirmed 's wake-promoting effects, showing dose-dependent increases in alertness comparable to but with enhanced potency at lower doses. These preclinical findings, conducted primarily in and cats, highlighted 's ability to sustain over extended periods without inducing hyperactivity or stereotypic behaviors associated with traditional stimulants. By the early 1980s, advanced to human clinical trials in , spearheaded by researchers Michel Jouvet and Hélène Bastuji. Initial open-label studies in patients with and demonstrated significant reductions in sleep attacks and drowsiness, with doses of 200–400 mg effectively improving daytime vigilance. A key 1988 trial involving 37 patients reported sustained benefits over periods up to three years, notably without peripheral side effects or disruption to nighttime architecture. Subsequent early trials extended these observations to sleep-deprived healthy volunteers, where effectively mitigated psychomotor and cognitive deficits. The transition from to gained momentum in the 1980s due to 's superior pharmacological profile. As a direct-acting compound, bypassed the need for hepatic required by , offering greater , faster onset, and reduced risk of liver enzyme elevation with chronic use. This shift allowed for more efficient dosing and minimized potential concerns, solidifying as the lead eugeroic candidate for further development.

Regulatory Milestones

The regulatory history of eugeroics, particularly and its derivative , reflects a progression from initial approvals for to broader indications, alongside evolving controls on access and availability. In the United States, the (FDA) first approved , marketed as Provigil by Cephalon, Inc., on December 24, 1998, for improving wakefulness in adults with excessive daytime sleepiness associated with . This approval marked the introduction of the first new treatment in the US in over four decades. Subsequent expansions broadened modafinil's indications. On October 24, 2003, the FDA approved its use for (SWSD). This was followed by approval on January 26, 2004, as an adjunct to standard treatments for residual excessive sleepiness in (OSA) patients. These expansions were supported by clinical trials demonstrating efficacy in improving without the typical side effects. Armodafinil, the R-enantiomer of modafinil and marketed as Nuvigil by Cephalon, received FDA approval on June 15, 2007, for similar indications: excessive sleepiness associated with OSA, narcolepsy, and SWSD. This approval provided a longer-acting formulation, with clinical data showing sustained wakefulness benefits comparable to modafinil. In Europe, modafinil's regulatory path began earlier, with initial authorization by French authorities in June 1992 for narcolepsy treatment, marking its first EU market entry. The European Medicines Agency (EMA) later centralized oversight, but approvals varied by member state; for instance, it was authorized in the UK for narcolepsy by 2002. However, national restrictions emerged due to safety concerns, and in July 2010, the EMA recommended limiting use to narcolepsy only, excluding OSA and SWSD, with prohibitions for children under 18 except in specific cases. Regarding controlled substance status in the , was classified as a Schedule IV drug under the effective January 27, 1999, reflecting its low potential for abuse relative to higher schedules. followed suit upon its 2007 approval, also designated Schedule IV by the . milestones significantly influenced eugeroics' accessibility. The primary for (U.S. Patent No. RE37,516) expired on April 6, 2012, after litigation delays, enabling generic entry and reducing costs for patients. Generic versions became widely available starting March 29, 2012, following resolution of exclusivity disputes. In , key patents had expired by 2005, facilitating earlier generic competition.

Pharmacology

Mechanism of Action

Eugeroics, such as and , primarily exert their wake-promoting effects through weak inhibition of the (DAT), which reduces and elevates extracellular levels in key brain regions like the and . This action occurs at low micromolar affinities, with exhibiting a Ki value of approximately 2.6 μM at DAT, significantly weaker than classical stimulants like (Ki ≈ 0.5 μM). The resulting increase in signaling enhances arousal and cognitive vigilance without the intense associated with stronger DAT inhibitors, as evidenced by studies showing 50-60% DAT occupancy at therapeutic doses of 200-400 mg. These agents also activate the (hypocretin) system in the , stabilizing by increasing orexin neuron activity and fos expression, and promotes arousal in orexin-deficient models, where effects are more pronounced than in wild-type subjects. Concurrently, eugeroics modulate other neurotransmitter systems: they decrease gamma-aminobutyric acid (GABA) release in cortical and hypothalamic regions, potentially via indirect serotonergic mechanisms, while increasing extracellular glutamate in the , hippocampus, and , thereby shifting the excitatory-inhibitory balance toward . neurotransmission is enhanced through indirect activation of neurons, further supporting sustained . Electroencephalography (EEG) studies demonstrate these neurochemical changes manifest as spectral power alterations, including reduced delta and waves (indicative of decreased sleep propensity) and increased alpha and gamma oscillations (associated with heightened and cognitive ). Unlike traditional stimulants, eugeroics lack direct at adrenergic or serotonergic receptors, with negligible binding affinities ( >100 μM) at alpha/beta-adrenergic sites and serotonin receptors, which contributes to their lower incidence of stimulant-like side effects such as or mood elevation. This selective profile underscores their atypical mechanism, focusing on subtle monoaminergic and peptidergic enhancements rather than broad receptor activation.

Pharmacokinetics

Eugeroics, such as and , exhibit favorable pharmacokinetic profiles that support their use in promoting wakefulness. is readily absorbed following , with absolute not determined due to poor aqueous but approximately equal to that of an aqueous suspension, leading to peak plasma concentrations occurring 2-4 hours after administration. Food intake may delay the time to peak concentration by approximately 1 hour but does not significantly alter overall . The elimination half-life of modafinil is 12-15 hours, while for armodafinil it is approximately 15 hours, enabling convenient once-daily dosing regimens for both agents. These half-lives reflect steady-state conditions following multiple doses, contributing to sustained therapeutic effects throughout the day. Metabolism of eugeroics occurs predominantly in the liver through cytochrome P450 enzymes, primarily CYP3A4 and CYP2C19, resulting in the formation of inactive metabolites such as modafinil acid and modafinil sulfone. Excretion is mainly renal, with less than 10% of the dose eliminated unchanged in the urine; the remainder is cleared as metabolites. Differences in stereoisomer pharmacokinetics account for variations in duration of action between modafinil and armodafinil. Modafinil is a racemic mixture of R- and S-enantiomers, with the S-enantiomer clearing more rapidly (half-life of 3-4 hours) compared to the R-enantiomer. Armodafinil, consisting solely of the R-enantiomer, exhibits slower clearance, leading to prolonged plasma exposure and extended wakefulness-promoting effects.

Medical Uses

Approved Indications

Eugeroics are primarily approved for the management of excessive daytime sleepiness (EDS) in specific sleep disorders, with modafinil and armodafinil serving as first-line agents in many cases. In the United States, the Food and Drug Administration (FDA) has approved these medications for narcolepsy, obstructive sleep apnea (OSA), and shift work sleep disorder (SWSD), while the European Medicines Agency (EMA) restricts modafinil primarily to narcolepsy. Additional eugeroics like solriamfetol have expanded options for EDS in narcolepsy and OSA, while pitolisant is approved for narcolepsy. For narcolepsy, eugeroics are indicated to improve wakefulness and reduce EDS, with some agents also addressing cataplexy. Modafinil, at a typical dose of 200 mg once daily in the morning, is recommended as a standard treatment for EDS in adults with narcolepsy, often helping to decrease cataplexy episodes as a secondary benefit. Armodafinil (150–250 mg once daily) and solriamfetol (75–150 mg once daily) are similarly approved for EDS in narcolepsy, while pitolisant (starting at 17.8 mg once daily, titrated up to 35.6 mg) is indicated for both EDS and cataplexy in adults. The American Academy of Sleep Medicine (AASM) strongly endorses modafinil, pitolisant, and solriamfetol for treating EDS in adults with narcolepsy, based on evidence of clinically significant improvements in wakefulness. In obstructive sleep apnea (OSA), eugeroics are approved as an adjunct to primary treatments like continuous positive airway pressure (CPAP) to address residual EDS. Modafinil (200 mg once daily) and armodafinil (150–250 mg once daily) improve wakefulness in patients with OSA who experience persistent sleepiness despite CPAP adherence, without treating the underlying airway obstruction. Solriamfetol (75–150 mg once daily) is also FDA-approved for this indication, enhancing residual wakefulness in adults. AASM guidelines support the use of modafinil and armodafinil in this context for adults over 16 years. For shift work sleep disorder (SWSD), eugeroics target EDS in night-shift workers by promoting alertness during work hours. Modafinil (200 mg taken one hour before the start of the shift) and armodafinil (150 mg one hour prior) are FDA-approved to improve wakefulness associated with irregular work schedules. These approvals are limited to adults, with AASM recommending their use in individuals over 16 years experiencing SWSD-related sleepiness.

Off-label and Investigational Applications

Eugeroics, particularly modafinil and armodafinil, have been explored off-label for attention-deficit/hyperactivity disorder (ADHD) in adults, where clinical trials demonstrate improvements in attention and executive function. However, guidelines do not recommend eugeroics as first-line therapy due to the established efficacy and longer safety data for stimulants such as methylphenidate. In treatment-resistant depression, eugeroics serve as adjuncts to antidepressants, with studies from the 2010s showing enhancements in motivation, fatigue, and residual symptoms. A 2013 systematic review and meta-analysis of randomized controlled trials of modafinil augmentation (100–200 mg/day) in unipolar and bipolar depression reported significant reductions in depressive symptoms, particularly apathy and anhedonia. Meta-analyses from this period, including a 2022 review of augmentation strategies, confirmed modafinil's moderate efficacy as an add-on therapy, improving Hamilton Depression Rating Scale scores by 4–6 points over antidepressants alone. These benefits are attributed to eugeroics' promotion of wakefulness without the abuse potential of traditional stimulants, though long-term data remain limited. Investigational applications include managing fatigue in multiple sclerosis (MS), where meta-analyses from 2020–2025 indicate moderate efficacy for modafinil. A 2024 systematic review of pharmacologic interventions found that modafinil (200 mg/day) reduced Fatigue Severity Scale scores by approximately 1.5 points versus placebo, with benefits persisting for 8–12 weeks and improvements in quality of life. However, a 2025 meta-analysis of 15 trials reported minimal overall effect sizes (standardized mean difference of 0.25), suggesting it as a second-line option after non-pharmacologic approaches like exercise. Similarly, for post-stroke recovery, eugeroics target fatigue and cognitive deficits; a 2023 meta-analysis of randomized trials showed modafinil improved post-stroke fatigue symptoms with a standardized mean difference of -0.82 (95% CI -1.31 to -0.34) at the end of treatment, aiding rehabilitation adherence. A 2025 narrative review of neurostimulants corroborated moderate gains in alertness and motor recovery, though larger trials are needed to confirm durability beyond 6 months. Cognitive enhancement in healthy individuals using eugeroics has garnered interest for military and student populations, but evidence is largely anecdotal and not clinically endorsed. Reviews indicate modest improvements in attention and memory during sleep deprivation, with a 2015 meta-analysis showing enhanced performance on complex tasks equivalent to 1–2 hours of additional sleep. A 2022 military-focused review noted potential for sustained operations, yet emphasized risks like dependency and ethical concerns over unproven long-term benefits. For students, a 2025 survey-linked analysis found self-reported use for exam preparation but no robust trial data supporting superior academic outcomes, with experts advising against non-medical application due to insufficient safety profiles in healthy users.

Adverse Effects and Safety

Common Side Effects

The most frequently reported common side effects of eugeroics, particularly modafinil, include headache, nausea, and nervousness, which are often dose-dependent and occur in a significant proportion of users. In clinical trials, headache has been observed in up to 34% of patients taking modafinil, nausea in 11%, and nervousness in 7%. These effects are generally mild to moderate and tend to diminish over time or with continued use. Insomnia and anxiety are also commonly experienced, particularly when eugeroics are administered later in the day, but these symptoms typically resolve with dose adjustment or discontinuation of the . Dry mouth and represent additional mild adverse reactions, which may be associated with subtle effects such as minor changes in or . In elderly populations, the incidence of these common side effects may be higher due to reduced clearance and slower of eugeroics like , necessitating lower starting doses and closer monitoring.

Serious Risks and Contraindications

Eugeroics, such as and , carry risks of severe dermatological reactions, including Stevens-Johnson (SJS) and (TEN), which are life-threatening conditions characterized by widespread and involvement. These reactions have been reported in both adult and pediatric patients, prompting the U.S. (FDA) to add prominent warnings to the prescribing for in 2007, emphasizing immediate discontinuation upon the onset of . Similar warnings apply to , with post-marketing reports confirming cases of SJS and other serious cutaneous adverse reactions (SCARs). The incidence is rare, estimated at less than 0.1% in clinical use, but the potential severity necessitates vigilant monitoring, particularly in the first few weeks of therapy. Cardiovascular risks associated with eugeroics include elevated blood pressure, tachycardia, and potential exacerbation of underlying heart conditions in susceptible individuals. Modafinil and armodafinil can increase heart rate and blood pressure, with clinical studies showing mean increases of 2-5 mmHg systolic and 1-3 bpm in heart rate among healthy adults, though greater effects occur in those with pre-existing hypertension. These agents are not recommended for patients with uncontrolled hypertension due to the risk of precipitating hypertensive crises or arrhythmias. Additionally, eugeroics may worsen outcomes in individuals with structural cardiac abnormalities, such as left ventricular hypertrophy or mitral valve prolapse, where they have been linked to chest pain, palpitations, and rare ischemic events. Cardiovascular monitoring is advised, especially in predisposed patients. Contraindications for eugeroics primarily include known hypersensitivity to the drug or its components, as well as specific cardiovascular conditions. Patients with a history of left ventricular hypertrophy or mitral valve prolapse who have previously experienced mitral valve prolapse syndrome should avoid these agents, as they may provoke serious cardiac complications. Uncontrolled hypertension is also a contraindication, given the sympathomimetic effects that could aggravate the condition. No absolute contraindications exist for most other comorbidities, but caution is urged in those with recent myocardial infarction or unstable angina. Psychiatric risks with eugeroics encompass induction or exacerbation of manic episodes, particularly in patients with or a history of . has been associated with new-onset , hallucinations, and agitation in vulnerable individuals, with case reports documenting switches from depression to during treatment. These effects stem from the drugs' activity, which can destabilize mood in predisposed patients, necessitating careful screening and monitoring for psychiatric symptoms. Concomitant use with antipsychotics or mood stabilizers may mitigate risks, but discontinuation is recommended if emerges. Regarding pregnancy, eugeroics are classified as FDA Pregnancy Category C, indicating that animal reproduction studies have shown adverse effects, but there are no adequate well-controlled studies in humans, and potential benefits may warrant use despite risks. Limited data from registries suggest a possible increased risk of congenital malformations, such as cardiac defects, with first-trimester exposure to modafinil, though confounding factors limit causality. As of 2025, an interim analysis of the modafinil/armodafinil Pregnancy Exposure Registry has indicated a potential increased risk of major congenital malformations, and a petition to the FDA seeks to contraindicate their use during pregnancy due to evidence of fetal harm from animal and emerging human data. Use during pregnancy should be restricted to cases where benefits outweigh risks, with counseling on contraception advised for women of childbearing potential. Breastfeeding is not recommended due to excretion in milk and potential infant effects.

List of Eugeroics

Marketed Agents

Modafinil, marketed under the brand name Provigil and available in generic forms, was approved by the U.S. (FDA) in December 1998 for the treatment of associated with . The typical dosing regimen is 100 to 200 mg administered orally once daily in the morning, with adjustments possible based on individual response and tolerability. It is widely available globally through prescription, though subject to restrictions in where it is classified as a psychotropic substance; personal import is allowed up to 6 grams with a prescription, without needing special import permissions. Armodafinil, sold as Nuvigil and in generics, represents the R-enantiomer of and was approved by the FDA in June to address similar indications, offering a longer duration of wakefulness-promoting effects due to its enantiopure composition. The standard dose is 150 mg taken orally once daily in the morning, with potential increases to 250 mg for certain patients. Like , is accessible worldwide via prescription, with regulatory oversight varying by country. Solriamfetol, marketed as Sunosi, received FDA approval in March 2019 for improving wakefulness in adults with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea. It functions as a dopamine and norepinephrine reuptake inhibitor, thereby enhancing monoaminergic neurotransmission to promote alertness. Dosing typically starts at 75 mg orally once daily, titrated up to a maximum of 150 mg based on efficacy and tolerance. Pitolisant, available as Wakix, was approved by the FDA in August specifically for excessive daytime sleepiness in adult patients with . This agent acts as an inverse at histamine H3 receptors, increasing histamine release in the to support wakefulness. The recommended starting dose is 8.9 mg orally once daily, with to 17.8 mg after 7 days and up to a maximum of 35.6 mg (two 17.8 mg tablets) as needed based on response and tolerability. It is prescribed internationally where approved, primarily for .

Discontinued and Developmental Agents

Adrafinil, the first synthetic eugeroic developed by Laboratoire L. Lafon in the late 1970s, was marketed in France under the brand name Olmifon from 1984 to 2011 for treating excessive daytime sleepiness associated with narcolepsy. It acts as a prodrug to modafinil, undergoing hepatic metabolism to produce the active wakefulness-promoting effects, but this process led to significant safety concerns. The drug was voluntarily discontinued by Cephalon in September 2011 due to an unfavorable risk-benefit ratio, primarily driven by reports of hepatotoxicity, including elevated liver enzymes and instances of severe liver injury with chronic use. In the United States, adrafinil was never approved by the FDA and remains available only as an unregulated dietary supplement, though health authorities advise against its use owing to the potential for liver damage without medical supervision. Early structural analogs of the benzhydryl sulfinyl series explored in the 1970s were investigated for wakefulness-promoting properties but ultimately abandoned due to inadequate efficacy in preclinical models and lack of advancement to clinical stages. These compounds, structurally distinct from the successful series that yielded and , failed to demonstrate consistent behavioral stimulation without unwanted side effects, leading researchers to pivot toward more promising derivatives. Among developmental eugeroics, agonists represent a promising class targeting the underlying deficiency in type 1. Danavorexton (TAK-925), a selective orexin 2 receptor developed by Takeda, has progressed through phase 1 trials demonstrating robust wake-promoting effects in healthy volunteers and preclinical models of , with ongoing phase 2 evaluations for sleep disorders including and opioid-induced respiratory depression. Similarly, oveporexton (TAK-861), another oral orexin 2 receptor-selective from Takeda, met all primary endpoints in two pivotal phase 3 trials (FirstLight and RadiantLight) announced in July 2025, showing significant improvements in , , and frequency in adults with type 1, positioning it for potential regulatory submission by early 2026. As of November 2025, Takeda has not yet submitted for regulatory approval. These agents aim to restore physiological arousal without the peripheral stimulation of traditional stimulants, though challenges like trial enrollment delays in related indications highlight ongoing developmental hurdles.

Research Directions

Novel Compounds

Recent advancements in eugeroic development have focused on sulfinyl benzhydryl derivatives that build upon the core of to enhance (DAT) inhibition while improving pharmacokinetic profiles. For instance, novel thio- and sulfinylacetamide analogues, such as those with phenyl ring substitutions (e.g., methyl or groups), demonstrate significantly higher DAT affinity compared to ; one compound achieved a Kᵢ of 114 nM, representing a 20-fold potency increase over 's Kᵢ of 2600 nM. Similarly, bisfluoro analogues like (S)-(+)-JBG1-048 and (R)-(-)-JBG1-049, which introduce atoms to the diphenylmethyl moiety, exhibit comparable DAT binding affinities to (R)- but produce longer-lasting elevations in extracellular levels in the shell, reaching up to 308% of baseline at 32 mg/kg doses in models. These structural innovations, particularly , aim to optimize blood-brain barrier (BBB) penetration and reduce metabolic liabilities associated with traditional sulfinyl derivatives. Fluorine substitution enhances and steric properties, facilitating improved CNS access without substantial efflux by transporters, as inferred from analogous DAT inhibitor studies. Additionally, such modifications minimize P450-mediated metabolism, potentially extending duration of action and reducing drug interactions, as seen in preclinical pharmacokinetic evaluations of related modafinil-like compounds. Shifting to non-sulfinyl classes, selective 2 (OX2R) agonists represent a promising category of eugeroics targeting the underlying deficiency in disorders like . Compounds such as oveporexton (TAK-861), with an EC₅₀ of 2.5 nM for OX2R and over 3000-fold selectivity over OX1R, advanced through clinical development, reaching phase 3 trials by 2025 with positive efficacy results. In phase 3 trials completed in 2025, oveporexton significantly improved wakefulness, daytime sleepiness, and in participants with type 1. Danavorexton (TAK-925), another OX2R-selective , demonstrated efficacy in preclinical orexin-deficient models but its phase 2 was discontinued in 2024 due to slow enrollment. Preclinical studies of these novel eugeroics highlight sustained wake-promoting effects without evidence of tolerance. In /ataxin-3 mice, TAK-861 at doses as low as 0.03 mg/kg increased total wake time during the active phase for up to 8 hours in cynomolgus monkeys, with no desensitization observed after 14 days of repeated dosing. Danavorexton similarly prolonged and reduced sleep fragmentation in murine models for at least 3 hours post-administration, maintaining efficacy over chronic 14-day treatment without tolerance development. Fluoro-modafinil analogues also support this profile, showing dose-dependent in rats without reported tolerance in short-term assays.

Emerging Therapeutic Areas

Preclinical and preliminary studies, including a 2025 animal model of , suggest potential benefits of in mitigating -related cognitive decline, with evidence from related dementias like disorders showing improvements in and global mental status, suggesting applicability to Alzheimer's . For instance, animal models of induced by demonstrated that mitigated memory impairments, supporting its role in addressing -related cognitive decline in early-stage Alzheimer's. Eugeroics are also showing promise in treating linked to , with 2024 pilot studies evaluating their in reducing . The NIH's RECOVER-SLEEP initiative includes ongoing randomized trials testing and in patients with post-acute sequelae of infection, focusing on symptoms. These efforts build on off-label precedents for disorders, highlighting eugeroics' potential to alleviate persistent fatigue in cohorts. In military contexts, eugeroics are under investigation for enhancing sustained during , including -funded research on strategies. The AWARE program, launched in 2024, aims to develop interventions combining pharmaceuticals like with non-drug methods to achieve rapid cognitive recovery post-sleep loss, minimizing off-target effects for warfighters in prolonged operations. Related studies have confirmed 's ability to maintain vigilance and over extended periods, with approaches explored to optimize alertness while reducing dosage-related risks. Despite these advances, challenges persist in evaluating dependency risks associated with chronic eugeroic use, with longitudinal studies ongoing through to assess long-term safety. While exhibits low abuse potential compared to traditional stimulants, rare cases of dependence have been documented, particularly in vulnerable populations, prompting scrutiny in extended therapeutic applications. Current research emphasizes monitoring for tolerance and withdrawal in chronic regimens, informing guidelines for safe integration into emerging indications.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC3286657/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC4386138/
  3. https://pubchem.ncbi.nlm.nih.gov/compound/Armodafinil
  4. https://pubmed.ncbi.nlm.nih.gov/19318599/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC5996886/
  6. https://pubmed.ncbi.nlm.nih.gov/30106194/
  7. https://www.sciencedirect.com/science/article/abs/pii/S0889159119314953
  8. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020717s037s038lbl.pdf
  9. https://pubmed.ncbi.nlm.nih.gov/32447354/
  10. https://go.drugbank.com/drugs/DB00745
  11. https://www.psychiatriapolska.pl/pdf-90687-81612?filename=81612.pdf
  12. https://www.ncbi.nlm.nih.gov/books/NBK531476/
  13. https://www.ncbi.nlm.nih.gov/books/NBK557437/
  14. https://pubmed.ncbi.nlm.nih.gov/36108771/
  15. https://www.federalregister.gov/documents/1999/01/27/99-1791/schedules-of-controlled-substances-placement-of-modafinil-into-schedule-iv
  16. https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf
  17. https://newdrugapprovals.org/2016/11/30/adrafinil/
  18. https://pubmed.ncbi.nlm.nih.gov/30174215/
  19. https://gwern.net/doc/modafinil/2018-billiard.pdf
  20. https://pubmed.ncbi.nlm.nih.gov/2906157/
  21. https://www.cambridge.org/core/journals/european-psychiatry/article/antagonism-by-modafinil-of-the-psychomotor-and-cognitive-impairment-induced-by-sleepdeprivation-in-12-healthy-volunteers/D1D833668139FB924B715B25CAB3B8FD
  22. https://www.sciencedirect.com/topics/medicine-and-dentistry/adrafinil
  23. https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020717A_Provigil.cfm
  24. https://elsevier.health/en-US/preview/modafinil
  25. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20717se1-008_provigil_lbl.pdf
  26. https://www.drugs.com/history/nuvigil.html
  27. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875_nuvigil_toc.cfm
  28. https://www.ema.europa.eu/en/documents/referral/modafinil-article-31-referral-annex-i-ii-iii-iv_en.pdf
  29. http://www.sefap.it/farmacovigilanza_news_201009/WC500094976.pdf
  30. https://www.govinfo.gov/content/pkg/FR-1999-01-27/html/99-1791.htm
  31. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf
  32. https://www.thefdalawblog.com/2012/04/dust-up-over-generic-provigil-180-day-exclusivity-quickly-ends-with-tropi-motion-withdrawal/
  33. https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2012/FDA-Decides-Teva-is-Sole-First-to-File-on-Provigil/default.aspx
  34. https://ec.europa.eu/commission/presscorner/detail/hu/ip_20_2220
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC2672878/
  36. https://academic.oup.com/ijnp/article/17/5/697/729714
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC6773149/
  38. https://pubmed.ncbi.nlm.nih.gov/15652995/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC2654794/
  40. https://pubmed.ncbi.nlm.nih.gov/22640618/
  41. https://www.sciencedirect.com/science/article/pii/S1878747923013259
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC3413742/
  43. https://www.nature.com/articles/1301534
  44. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020717s030s034s036lbl.pdf
  45. https://pubmed.ncbi.nlm.nih.gov/12537513/
  46. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021875s005s008s015lbl.pdf
  47. https://www.sciencedirect.com/science/article/abs/pii/S0149291810003711
  48. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020717s020s013s018lbl.pdf
  49. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021875s023lbl.pdf
  50. https://www.ema.europa.eu/en/medicines/human/referrals/modafinil
  51. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
  52. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211150s003lbl.pdf
  53. https://pubmed.ncbi.nlm.nih.gov/34743789/
  54. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(24)00360-2/fulltext
  55. https://www.psychiatrist.com/jcp/modafinil-augmentation-therapy-unipolar-bipolar-depression/
  56. https://www.sciencedirect.com/science/article/abs/pii/S0165032721014518
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC4761633/
  58. https://onlinelibrary.wiley.com/doi/full/10.1002/brb3.3623
  59. https://www.sciencedirect.com/science/article/pii/S2211034825000951
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC10614171/
  61. https://www.ahajournals.org/doi/10.1161/STROKEAHA.124.048677
  62. https://www.ox.ac.uk/news/2015-08-20-review-%25E2%2580%2598smart-drug%25E2%2580%2599-shows-modafinil-does-enhance-cognition
  63. https://pubmed.ncbi.nlm.nih.gov/34632515/
  64. https://edintegrity.biomedcentral.com/articles/10.1007/s40979-024-00174-3
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC3557439/
  66. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=514d242d-48c9-4162-a85a-a433b41107ac
  67. https://www.rxlist.com/provigil-drug.htm
  68. https://www.mayoclinic.org/drugs-supplements/modafinil-oral-route/description/drg-20064870
  69. https://www.drugs.com/compare/lithium-vs-modafinil
  70. https://womensmentalhealth.org/posts/modafinil-pregnancy/
  71. https://www.citizen.org/news/the-fda-must-require-contraindicating-the-use-of-two-commonly-prescribed-stimulants-during-pregnancy/
  72. https://www.neurology.org/doi/10.1212/CPJ.0000000000200551
  73. https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20717lbl.pdf
  74. https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/01.html
  75. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000SumR.pdf
  76. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211230Orig1s007lbl.pdf
  77. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211150s000lbl.pdf
  78. https://psychiatryonline.org/doi/full/10.1176/appi.ajp-rj.2021.170105
  79. https://pubmed.ncbi.nlm.nih.gov/36934366/
  80. https://www.takeda.com/newsroom/newsreleases/2025/takeda-orexin-data-oveporexton-phase-3-narcolepsy-world-sleep-2025/
  81. https://www.fiercebiotech.com/biotech/takeda-stops-phase-2-sleep-apnea-trial-over-slow-enrollment
  82. https://pubs.acs.org/doi/10.1021/jm401754x
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC8294075/
  84. https://www.mdpi.com/1422-0067/24/23/16956
  85. https://www.nature.com/articles/s41598-024-70594-1
  86. https://www.nejm.org/doi/abs/10.1056/NEJMoa2405847
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC9436334/
  88. https://www.researchgate.net/publication/256612352_Modafinil_and_armodafinil_improve_attention_and_global_mental_status_in_Lewy_bodies_disorders_Preliminary_evidence
  89. https://pubs.acs.org/doi/10.1021/acsptsci.4c00618
  90. https://www.nih.gov/news-events/news-releases/nih-open-long-covid-clinical-trials-study-sleep-disturbances-exercise-intolerance-post-exertional-malaise
  91. https://www.cidrap.umn.edu/covid-19/nih-announces-long-covid-trials-examine-treatments-sleep-exercise-disruptions
  92. https://clinicaltrials.gov/study/NCT06404099
  93. https://www.darpa.mil/news/2024/warfighter-alertness
  94. https://www.dvidshub.net/news/548785/wrair-hosts-review-darpas-alert-warfighter-enablement-program
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC4319252/
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC5912487/
  97. https://www.thehopehouse.com/modafinil-addiction/
  98. https://www.droracle.ai/articles/15209/long-term-effects-of-modafinil
Add your contribution
Related Hubs
User Avatar
No comments yet.